NasdaqCM - Delayed Quote USD

Evoke Pharma, Inc. (EVOK)

0.4580

+0.0130

(+2.92%)

At close: 3:58 PM EDT

Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications

Michael Cline, DO., Medical Director Gastroparesis Clinic, Cleveland Clinic to presentSOLANA BEACH, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced it will host a virtual KOL and investor webinar on Wednesday, April 24 at 12:00 p.m. ET. Moderated by Yale Jen, PhD, Senior Managing Director of Equity

GlobeNewswire 9 days ago

EVOK
+2.92%
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer

SOLANA BEACH, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that Matthew J. D’Onofrio will be succeeding David A. Gonyer as Chief Executive Officer as of March 31, 2024 upon Mr. Gonyer’s departure for personal reasons. Mr. D’Onofrio currently serves as President and Chief Operating Officer. “Worki

GlobeNewswire last month

EVOK
+2.92%
Evoke Pharma, Inc. (NASDAQ:EVOK): Are Analysts Optimistic?

We feel now is a pretty good time to analyse Evoke Pharma, Inc.'s ( NASDAQ:EVOK ) business as it appears the company...

Simply Wall St. last month

EVOK
+2.92%
Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2023 Earnings Call Transcript

Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2023 Earnings Call Transcript March 14, 2024 Evoke Pharma, Inc. misses on earnings expectations. Reported EPS is $-0.59 EPS, expectations were $-0.5. Evoke Pharma, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, […]

Insider Monkey last month

EVOK
+2.92%
Q4 2023 Evoke Pharma Inc Earnings Call

Q4 2023 Evoke Pharma Inc Earnings Call

Thomson Reuters StreetEvents last month

EVOK
+2.92%
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results

Evoke Pharma, Inc. Balance Sheet Evoke Pharma, Inc. Statement of Operations Fiscal year 2023 net product sales from prescriptions totaled approximately $5.2M, a 107% increase from 2022 Company projects $14M in net revenue for 2024 SOLANA BEACH, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced i

GlobeNewswire last month

EVOK
+2.92%
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024

SOLANA BEACH, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, today announced that the Company is scheduled to release its fourth quarter and full year 2023 on Thursday, March 14, 2024, after the market closes. Management will host a conference call and webcast with accompanying slides on Thursday, March 14, 2024, at 4

GlobeNewswire last month

EVOK
+2.92%
Evoke Pharma Announces Closing of $7.5 Million Public Offering

Potential for Additional $22.5 Million in the Event of Exercise of Common Warrants in FullSOLANA BEACH, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced today that it has closed an underwritten public offering led by Nantahala Capital Management, with participation by other fundamental investors, for

GlobeNewswire 2 months ago

EVOK
+2.92%
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million

SOLANA BEACH, Calif., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced today that it has priced an underwritten public offering led by Nantahala Capital Management, with participation by other fundamental investors, for gross proceeds of up to $30 million, that includes initial upfront funding of approximatel

GlobeNewswire 2 months ago

EVOK
+2.92%
Revolutionizing gastroparesis treatment: Evoke Pharma's CEO talks game-changing nasal spray

Evoke Pharma CEO Dave Gonyer joined Steve Darling from Proactive to share news the company has achieved a significant milestone with the listing of its recently issued U.S. patent related to GIMOTI...

News Direct 4 months ago

EVOK
+2.92%
Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent

GIMOTI now holds four listed patents with coverage through 2029SOLANA BEACH, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that its recently issued U.S. patent related to GIMOTI, No. 11,813,231 is now listed in the U.S. Food and Drug Administration (FDA) publication, “Approved Drug Products with Th

GlobeNewswire 4 months ago

EVOK
+2.92%
United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI

The Company Will Submit for FDA Orange-Book Listing in the Near TermSOLANA BEACH, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,813,231 titled “Nasal Formulations of Metoclopramide”, pertaining to the Company’s com

GlobeNewswire 5 months ago

EVOK
+2.92%
Evoke Pharma Reports Third Quarter 2023 Financial Results

38% Revenue Increase Compared to Q2 2023; 88% Increase Year-Over-Year Seventh Straight Prescription Fill Increase Since Q1 2022 21% Increase Compared to Q2 2023; 95% Increase Year-Over-Year “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” Presented at The American College of Gastroenterology (ACG) 2023 Annual Meeting SOLANA BEACH, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDA

GlobeNewswire 5 months ago

EVOK
+2.92%
Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023

Reduction in emergency department visits, hospitalizations and office visits caused diabetic gastroparesis patients and insurers to save over $15,000 for each patient in a six-month period by treating with GIMOTI versus oral metoclopramide Image 1 All-Cause HCRU visits in 6-month post-index period for NMCP and OMCP patients Image 2 All-Cause HRCU Costs between NMCP and OMCP patients over 6-month post index period SOLANA BEACH, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:

GlobeNewswire 5 months ago

EVOK
+2.92%
7 Under-the-Radar Growth Stocks Ready to Make a Splash

If I’m looking to outperform the market over time, I’m usually going to buy growth stocks. While value stocks have a place in any portfolio, growth stocks are the ones that keep the returns rolling in. Usually, companies represented by growth stocks are innovative and quickly adapt to changing times. By being involved in some of the most creative industries, such as biotechnology, technology and green energy, growth stocks help you capitalize on emerging trends and technologies. I also like grow

InvestorPlace 6 months ago

SMCI

RGTI

EVOK
+2.92%
Evoke Pharma’s Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presented at The American College of Gastroenterology (ACG) 2023 Annual Meeting

Selected for a Distinguished Oral Plenary PresentationSOLANA BEACH, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that its real-world healthcare utilization data suggesting reduced healthcare costs for patients on GIMOTI versus patients on oral metoclopramide will be presented, as an oral plenary p

GlobeNewswire 6 months ago

EVOK
+2.92%
Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®

SOLANA BEACH, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that it has been granted a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application No. 17/366,829 pertaining to GIMOTI, the first and only FDA-approved nasal formulation of metoclopramide commercially

GlobeNewswire 7 months ago

EVOK
+2.92%
Evoke Pharma Reports Second Quarter 2023 Financial Results

40% revenue growth compared to Q1 2023 34% increase in prescription fills compared to Q1 2023 Presented industry-leading real-world healthcare utilization data supporting the benefits of GIMOTI compared to oral metoclopramide at DDW 2023; additional abstracts accepted at future medical conferences SOLANA BEACH, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an

GlobeNewswire 8 months ago

EVOK
+2.92%
Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting

Real-world study that explored the healthcare utilization resource utilization among patients receiving GIMOTI with and without prior treatment with oral metoclopramide Both organizations recognize and support Gastroparesis Awareness Month through continued support of the International Foundation for Gastrointestinal Disorders (IFFGD) SOLANA BEACH, Calif. and CHICAGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on trea

GlobeNewswire 8 months ago

EVOK
+2.92%
Evoke Pharma and EVERSANA Announce Abstract Selection for Plenary Oral Presentation at The American College of Gastroenterology (ACG) 2023 Annual Meeting

“Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients”SOLANA BEACH, Calif., and CHICAGO, July 25, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, and EVERSANA™, a leading provider of global commercial services to the life science indu

GlobeNewswire 8 months ago

EVOK
+2.92%

Performance Overview

Return	EVOK	S&P 500
YTD	-56.38%	+6.92%
1-Year	-76.39%	+25.26%
3-Year	-97.83%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Evoke Pharma, Inc. (EVOK)

Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications

Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer

Evoke Pharma, Inc. (NASDAQ:EVOK): Are Analysts Optimistic?

Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2023 Earnings Call Transcript

Q4 2023 Evoke Pharma Inc Earnings Call

Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results

Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024

Evoke Pharma Announces Closing of $7.5 Million Public Offering

Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million

Revolutionizing gastroparesis treatment: Evoke Pharma's CEO talks game-changing nasal spray

Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent

United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI

Evoke Pharma Reports Third Quarter 2023 Financial Results

Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023

7 Under-the-Radar Growth Stocks Ready to Make a Splash

Evoke Pharma’s Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presented at The American College of Gastroenterology (ACG) 2023 Annual Meeting

Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®

Evoke Pharma Reports Second Quarter 2023 Financial Results

Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting

Evoke Pharma and EVERSANA Announce Abstract Selection for Plenary Oral Presentation at The American College of Gastroenterology (ACG) 2023 Annual Meeting

Performance Overview